Georgia's Online Cancer Information Center

Find A Treatment Site

Northside Hospital Cancer Institute - Forsyth

Treatment Sites in Georgia

Primary Location

1200 Northside Forsyth Drive
Suite 140
Cumming, GA 30041
770-292-7000 (p)
www.northside.com

driving directions

Clinical Trials in Georgia

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Cancer Type: Unspecified

A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Cancer Type: Unspecified

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I / II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4 / RTOG-3515)
Cancer Type: Lung Cancer

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Cancer Type: Ovarian Cancer

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Cancer Type: Unspecified

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Cancer Type: Unspecified

Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens
Cancer Type: Breast Cancer

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.